Published in Drug Healthc Patient Saf on October 28, 2009
Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med (2013) 1.19
Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol (2013) 1.04
Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther (2013) 1.00
A review of the gastrointestinal safety data--a gastroenterologist's perspective. Rheumatology (Oxford) (2010) 0.99
Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? Aliment Pharmacol Ther (2013) 0.82
Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis (2013) 0.80
COX-2 Inhibitors and Gastric Cancer. Gastroenterol Res Pract (2014) 0.78
The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther (2013) 0.76
Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol (2015) 0.76
Imprudent Gastro-protective Approach in Majority of Specialists' Clinics of a Tertiary Hospital. J Clin Diagn Res (2016) 0.75
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA (1995) 45.41
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet (1988) 10.82
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 9.77
Approaches to heterogeneity in meta-analysis. Stat Med (2001) 7.85
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med (2003) 6.77
Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.40
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25
Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost (2003) 4.24
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med (1998) 4.24
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology (1999) 4.13
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med (1998) 3.96
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA (2002) 3.61
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA (1999) 3.60
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology (2006) 3.35
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med (2001) 3.02
Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ (2000) 3.02
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med (2006) 2.87
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med (2002) 2.78
Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med (1993) 2.74
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (2000) 2.63
Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ (1988) 2.48
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med (1996) 2.37
Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol (1996) 2.30
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology (2004) 2.28
COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. J Clin Rheumatol (2001) 2.09
Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol (1998) 2.02
Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev (2002) 2.01
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc (1999) 1.96
Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol (2007) 1.94
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology (2004) 1.79
Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med (1991) 1.68
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol (2001) 1.64
A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol (2002) 1.61
Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract (2002) 1.61
Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol (2004) 1.59
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology (1997) 1.59
Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med (1993) 1.58
Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc (2005) 1.52
Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern. Drug Saf (2006) 1.42
Double blind, placebo controlled trial on the cytoprotective effect of misoprostol in subjects with rheumatoid arthritis, osteoarthritis and seronegative spondarthropathy on NSAIDs. J Assoc Physicians India (1991) 1.39
Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy (1999) 1.39
Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther (2008) 1.38
Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther (2005) 1.34
Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum (2003) 1.32
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med (2000) 1.30
Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol (2000) 1.28
Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther (2001) 1.26
Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evaluation. Arch Intern Med (1987) 1.25
Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology (2006) 1.21
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) (2002) 1.20
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol (2001) 1.18
The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol (2003) 1.17
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther (1999) 1.16
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin (2005) 1.16
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A (2001) 1.13
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med (2001) 1.12
Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther (2003) 1.11
Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol (1996) 1.10
Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther (1998) 1.07
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis (2004) 1.06
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med (2005) 1.04
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J Rheumatol (1999) 1.04
Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. J Gen Intern Med (2005) 1.04
Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med (1995) 1.02
Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med (2000) 1.01
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract (2002) 1.00
Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res (2002) 1.00
Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol (2003) 0.99
Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci (1989) 0.98
Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther (2001) 0.94
Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin (2002) 0.94
The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol (2000) 0.94
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin (2005) 0.93
Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther (2004) 0.92
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol (2002) 0.92
Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial. Scand J Rheumatol (1994) 0.92
A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol (1992) 0.92
A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin (2003) 0.92
Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med (1987) 0.88
The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol (1996) 0.88
Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract (2004) 0.86
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) (2001) 0.86
Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. J Clin Rheumatol (2000) 0.86
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. Aliment Pharmacol Ther (2003) 0.85
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol (2007) 13.46
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) (2012) 9.25
Developing core outcome sets for clinical trials: issues to consider. Trials (2012) 8.39
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Campaign to revitalise academic medicine kicks off. BMJ (2004) 6.94
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol (2010) 5.78
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet (2010) 5.05
Who cares about academic medicine? BMJ (2004) 4.46
Validation of a new scale for the assessment of bowel preparation quality. Gastrointest Endosc (2004) 4.38
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Open letter to the leader of academic medicine. BMJ (2007) 4.06
Five futures for academic medicine. PLoS Med (2005) 3.95
Evidence-based clinical guidelines for immigrants and refugees. CMAJ (2010) 3.57
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology (2006) 3.35
Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. Can J Gastroenterol (2012) 3.15
Quality of life of individuals with heart failure: a randomized trial of the effectiveness of two models of hospital-to-home transition. Med Care (2002) 3.05
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet (2008) 2.83
What types of interventions generate inequalities? Evidence from systematic reviews. J Epidemiol Community Health (2012) 2.80
Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev (2009) 2.61
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. PLoS Med (2012) 2.31
A comparison of the quality of Cochrane reviews and systematic reviews published in paper-based journals. Eval Health Prof (2002) 2.29
Flossing for the management of periodontal diseases and dental caries in adults. Cochrane Database Syst Rev (2011) 2.29
Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med (2012) 2.23
A randomized prospective trial comparing different regimens of oral sodium phosphate and polyethylene glycol-based lavage solution in the preparation of patients for colonoscopy. Gastrointest Endosc (2006) 2.12
Canada urgently needs a national network of libraries to access evidence. Healthc Q (2006) 2.07
[Current management of nonvariceal upper gastrointestinal bleeding in Spain]. Gastroenterol Hepatol (2012) 2.04
Avoidable mortality by neighbourhood income in Canada: 25 years after the establishment of universal health insurance. J Epidemiol Community Health (2007) 2.02
Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol (2008) 1.99
Complex interventions and their implications for systematic reviews: a pragmatic approach. J Clin Epidemiol (2013) 1.98
Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol (2007) 1.94
Gastric cancer susceptibility is not linked to pro-and anti-inflammatory cytokine gene polymorphisms in whites: a Nationwide Multicenter Study in Spain. Am J Gastroenterol (2007) 1.92
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol (2005) 1.81
Guidance for evidence-informed policies about health systems: rationale for and challenges of guidance development. PLoS Med (2012) 1.81
A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol (2009) 1.81
Efficacy of continuous passive motion following total knee arthroplasty: a metaanalysis. J Rheumatol (2004) 1.80
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ (2009) 1.76
Randomized controlled trial on low level laser therapy (LLLT) in the treatment of osteoarthritis (OA) of the hand. Lasers Surg Med (2005) 1.75
A checklist to evaluate a report of a nonpharmacological trial (CLEAR NPT) was developed using consensus. J Clin Epidemiol (2005) 1.74
Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol (2013) 1.73
Knowledge translation in developing countries. J Contin Educ Health Prof (2006) 1.73
Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol (2007) 1.64
Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev (2002) 1.62
Guidance for evidence-informed policies about health systems: assessing how much confidence to place in the research evidence. PLoS Med (2012) 1.62
Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol (2008) 1.62
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev (2013) 1.62
Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev (2014) 1.60
Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11. J Rheumatol (2014) 1.56
Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology (2013) 1.55
Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns (2002) 1.53
Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.53
Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol (2010) 1.51
A qualitative study of physicians' perceptions of three decision aids. Patient Educ Couns (2003) 1.49
Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials (2013) 1.47
Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies. J Natl Cancer Inst (2013) 1.47
Evaluation of current tobacco curriculum at 12 US medical schools. J Cancer Educ (2004) 1.47
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.44
A research and development agenda for systematic reviews that ask complex questions about complex interventions. J Clin Epidemiol (2013) 1.44
Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. Thromb Haemost (2013) 1.43
Cubilin and amnionless mediate protein reabsorption in Drosophila nephrocytes. J Am Soc Nephrol (2012) 1.42
Consumer-driven health care: building partnerships in research. Health Expect (2005) 1.42
Integrating prevention of mother-to-child HIV transmission programs to improve uptake: a systematic review. PLoS One (2012) 1.40
When does a good practice statement not justify an Evidence Based Guideline? J Clin Epidemiol (2015) 1.40
Inequity in primary and secondary preventive care for acute myocardial infarction? Use by socioeconomic status across middle-aged and older patients. Can J Cardiol (2013) 1.40
Funding agencies in low- and middle-income countries: support for knowledge translation. Bull World Health Organ (2008) 1.39
A survey of the decision-making needs of Canadians faced with complex health decisions. Health Expect (2003) 1.39
Occupational therapists should be more involved in the Cochrane Collaboration: the example of the Australian Cochrane Musculoskeletal Review Group. Aust Occup Ther J (2008) 1.38
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol (2007) 1.35
Damned if you do, damned if you don't: subgroup analysis and equity. J Epidemiol Community Health (2011) 1.35
Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.34
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology. Can J Clin Pharmacol (2009) 1.30
Indicators of safety compromise in gastrointestinal endoscopy. Can J Gastroenterol (2012) 1.30
Understanding and overcoming the barriers of implementing patient decision aids in clinical practice. J Eval Clin Pract (2006) 1.27
Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). Arthritis Res Ther (2004) 1.27
Comparison of total hip arthroplasty performed with and without cement : a randomized trial. J Bone Joint Surg Am (2002) 1.25
Tobacco control competencies for US medical students. Am J Public Health (2005) 1.25
Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.22
An evaluation of gender equity in different models of primary care practices in Ontario. BMC Public Health (2010) 1.19
Update of strategies to translate evidence from cochrane musculoskeletal group systematic reviews for use by various audiences. J Rheumatol (2013) 1.18
Interdental brushing for the prevention and control of periodontal diseases and dental caries in adults. Cochrane Database Syst Rev (2013) 1.18
Decision quality instrument for treatment of hip and knee osteoarthritis: a psychometric evaluation. BMC Musculoskelet Disord (2011) 1.17
Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. Gastrointest Endosc (2012) 1.15
Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. Gastroenterology (2012) 1.15
Use of telephone care in a cardiovascular disease management programme for type 2 diabetes patients in Santiago, Chile. Chronic Illn (2006) 1.14
How effects on health equity are assessed in systematic reviews of interventions. Cochrane Database Syst Rev (2010) 1.14
The uptake of integrated perinatal prevention of mother-to-child HIV transmission programs in low- and middle-income countries: a systematic review. PLoS One (2013) 1.14
The effects of an 'explicit' values clarification exercise in a woman's decision aid regarding postmenopausal hormone therapy. Health Expect (1999) 1.13
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol (2006) 1.13
Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology (2010) 1.11
Ottawa Panel evidence-based clinical practice guidelines on therapeutic massage for low back pain. J Bodyw Mov Ther (2012) 1.11
How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. J Rheumatol (2014) 1.11
Early postoperative mortality following joint arthroplasty: a systematic review. J Rheumatol (2011) 1.08